Drenthen W, Voors A A, Kappelle J L J, van Veldhuisen D J
Neth Heart J. 2005 Apr;13(4):142-146.
The results of the Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) study show that treatment with an angiotensin receptor blocker (ARB) in the acute phase of a stroke improves mortality and cardiovascular morbidity. In addition, direct comparative antihypertensive trials have demonstrated beneficial effects of ARBs in preventing stroke. These possible cerebro-protective effects of ARBs are supported by animal studies, demonstrating that stimulation of the AT2 receptor was related to a reduction in both cerebral infarct size and mortality. In the present report, we review both pathophysiological and clinical evidence for possible cerebroprotective effects of ARBs, independent of their effect on blood pressure.
坎地沙坦酯急性期治疗卒中幸存者（ACCESS）研究结果表明，卒中急性期使用血管紧张素受体阻滞剂（ARB）治疗可改善死亡率和心血管疾病发病率。此外，直接比较抗高血压药物的试验已证明ARB在预防卒中方面具有有益作用。动物研究支持了ARB这些可能的脑保护作用，表明刺激AT2受体与脑梗死面积和死亡率降低有关。在本报告中，我们综述了ARB可能具有脑保护作用的病理生理学和临床证据，而不考虑其对血压的影响。
